...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Ophthalmology: The International Journal of Ophthalmology >Intravitreal bevacizumab for symptomatic retinal arterial macroaneurysm.
【24h】

Intravitreal bevacizumab for symptomatic retinal arterial macroaneurysm.

机译：含有嗜型症状视网膜动脉瘤的玻璃体内贝伐单抗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To evaluate the therapeutic effect of intravitreal bevacizumab injection for symptomatic retinal arterial macroaneurysm.Retrospective interventional case series.The study included 23 patients (23 eyes) with symptomatic retinal arterial macroaneurysm. They were categorized according to treatment method into 2 groups: an intravitreal bevacizumab-treated group (11 eyes) and an untreated group (12 eyes). Bevacizumab was injected at the initial visit, followed by as-needed monthly reinjection. Best-corrected visual acuity (BCVA) and central macular thickness were documented and analyzed between groups.The mean follow-up period for all subjects was 10.83 ± 4.6 months. The mean number of injections for the treated group was 1.42 ± 0.69. The mean logarithm of the minimal angle of resolution (logMAR) of BCVA improved from baseline at the last follow-up by 0.26 in the bevacizumab-treated group (P = .02) and by 0.34 in the untreated group (P = .005). Average central macular thickness decreased from 384.4 ± 150.1 μm to 265 ± 112.5 μm in the bevacizumab-treated group (P = .0002) and from 413.2 ± 155.2 μm to 236.3 ± 103.5 μm in the untreated group (P = .008). The BCVA was significantly improved from baseline after 1 month in the bevacizumab-treated group (P = .02) and after 3 months in the untreated group (P = .01). However, there was no statistically significant difference in BCVA improvement or central macular thickness improvement achieved at the final visit.Intravitreal bevacizumab injection likely hastens resolution of macular edema and hemorrhage secondary to retinal arterial macroaneurysm. Intravitreal bevacizumab injection could be an effective treatment option for symptomatic retinal arterial macroaneurysm.
机译：为了评估玻璃体外贝伐单抗注射症对症状视网膜动脉大鼠的治疗效果。患有症状视网膜动脉大鼠症状的研究包括23名患者（23只眼）。它们根据治疗方法分类为2组：玻璃体内贝伐单抗治疗组（11只眼）和未处理的基团（12只眼）。 Bevacizumab在初次访问时注入，然后按照需要的每月再次重新注明。记录并在组之间进行了最佳校正的视力（BCVA）和中央黄斑厚度。所有受试者的平均随访时间为10.83±4.6个月。治疗组的平均注射次数为1.42±0.69。 BCVA分辨率最小角度（Logmar）的平均对数从Bevacizumab治疗组（P = .02）中最后随访的基线改善0.26，并在未处理基团中乘0.34（P = .005） 。在未处理基团中，平均中央黄斑厚度从384.4±150.1μm降低到265±150.1μm至265±112.5μm，在未处理的组中413.2±155.2μm至236.3±103.5μm在贝伐单抗治疗组（P = 0.02）和未处理基团中3个月后，BCVA从基线显着改善（p = .01）。然而，在最终访问中达到的BCVA改善或中央黄斑厚度改善没有统计学上显着差异。坦培北伐木子弹注射液可能加速了黄斑水肿和继发于视网膜动脉大鼠的出血的分辨率。玻璃体内贝伐单抗注射液可能是对症状视网膜动脉大草肌瘤的有效治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号